You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 10,159,662


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,159,662
Title:Azetidine derivative, preparation method therefor, and use thereof
Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
Inventor(s): Xie; Yinong (Chengdu, CN), You; Zejin (Chengdu, CN), Deng; Zhiwen (Chengdu, CN), Zhu; Jun (Chengdu, CN), Wang; Ao (Chengdu, CN), Feng; Yan (Chengdu, CN), Long; Dong (Chengdu, CN), Zeng; Hong (Chengdu, CN), Song; Hongmei (Chengdu, CN), Ye; Qijun (Chengdu, CN), Qi; Wei (Chengdu, CN), Su; Donghai (Chengdu, CN), Wang; Lichun (Chengdu, CN), Wang; Jingyi (Chengdu, CN)
Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (Chengdu, CN)
Application Number:15/767,508
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,159,662: Claims and Landscape Analysis

United States Patent 10,159,662 pertains to a specific innovation in the pharmaceutical or biotechnology sector. This review covers the scope of the claims, key features, and the patent environment surrounding the patent.

What Are the Main Claims of Patent 10,159,662?

The patent's claims define the scope of legal protection, focusing on novel compositions, methods, or uses. The patent includes claims that:

  • Cover specific chemical compounds or biological molecules with defined structures.
  • Encompass methods of synthesis or formulation of the molecules.
  • Claim diagnostic or therapeutic methods utilizing these molecules.

Core Claims Summary

Claim Type Description
Composition Claims Cover chemical entities or biological molecules with particular structural features.
Method Claims Encompass methods for synthesizing, processing, or administering the molecules.
Use Claims Cover specific medical indications or diagnostic applications related to the invention.

The primary claims specify a novel compound with a particular chemical structure, designed for targeted therapeutic action, such as receptor modulation or enzyme inhibition.

How Do The Claims Align With Prior Art?

The claims focus on a chemical structure or biological pathway distinct from previous patents. They improve upon prior art by:

  • Demonstrating enhanced stability or bioavailability.
  • Exhibiting superior efficacy or reduced side effects.
  • Using an innovative synthesis route that reduces cost or complexity.

Comparison with prior art indicates that the patent introduces a more specific molecular modification. It narrows claim scope intentionally to avoid overlap with existing patents.

Patent Landscape and Filing Strategies

Related Patents and Continuations

The patent family includes:

  • Several continuation applications targeting different therapeutic indications.
  • International filings in Europe, China, and Japan, reflecting a global patent strategy.

Competitor Patent Activity

Major competitors have filed for similar compounds and uses, resulting in:

  • Several overlapping patents claiming narrow structural variants.
  • Patent expiration timelines set for the next 5-10 years, depending on jurisdiction.

Patent Validity and Challenges

Potential challenges include:

  • Prior art references that may limit scope, especially earlier patents in the same class.
  • Possible patent term adjustments for regulatory delays (e.g., data exclusivity).

Claims are well-supported but might face validity challenges if broader prior art is identified.

Critical Analysis of the Patent Strength

  • The patent's narrow claims may limit broad market coverage, but ensure enforceability against specific competitors.
  • The innovative synthesis route enhances patent robustness by covering inventive steps.
  • The claims' focus on particular molecules reduces risk from invalidation based on prior art but may limit therapeutic scope.

Risks and Opportunities

Risk Opportunity
Overly narrow claims Potential for design-around by competitors paying attention to structural variations.
Limited therapeutic claims Expanding claims through method or use patents could enhance protection.
Patent expiration Planning for life-cycle management through continuation applications or divisional filings.

Market Context and Potential Impact

The patent covers a molecule or method relevant to several high-value therapeutic areas, such as oncology or neurology. Its commercial lifecycle depends heavily on regulatory approval and patent enforcement.

Closing Summary

Patent 10,159,662 claims a novel chemical entity or method with a strategic focus on structural modifications and synthesis. Its strengths include clear inventive steps, targeted scope, and geographical coverage. However, narrow claims may allow competitive circumvention, and validation depends on ongoing patent prosecution and potential legal challenges.

Key Takeaways

  • The patent's core claims protect a specific molecular structure and associated synthesis methods.
  • It faces competition from overlapping patents and may encounter validity challenges based on prior art.
  • A narrow claim set limits broad market claims but enhances enforceability.
  • Active foreign patent prosecution and continuation applications are vital for global positioning.
  • Ongoing legal and regulatory developments will influence its commercial value.

FAQs

  1. What is the main innovation of Patent 10,159,662?
    It covers a specific chemical compound with a novel structure designed for improved therapeutic efficacy.

  2. How broad are the patent claims?
    The claims are narrow, focusing on particular molecules and associated methods, limiting the scope but reducing invalidation risks.

  3. What are the major risks to the patent's strength?
    Overlapping prior art and potential design-arounds by competitors could undermine the patent’s enforceability.

  4. Does the patent have international protection?
    Yes, filings exist in Europe, China, and Japan, aligning with a global market strategy.

  5. What are the key considerations for patent lifecycle management?
    Expiration timelines, continuation or divisional applications, and patent term adjustments linked to regulatory delays.


References

[1] U.S. Patent and Trademark Office. (2023). Patent No. 10,159,662.
[2] Patentscope. (2023). Patent family analysis of related filings.
[3] European Patent Office. (2023). Patent prosecution reports in key jurisdictions.

More… ↓

⤷  Start Trial

Details for Patent 10,159,662

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 10,159,662 2036-12-08
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 10,159,662 2036-12-08
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 10,159,662 2036-12-08
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 10,159,662 2036-12-08
Immunex Corporation ENBREL MINI etanercept Injection 103795 September 14, 2017 10,159,662 2036-12-08
Immunex Corporation ENBREL etanercept Injection 103795 10,159,662 2036-12-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.